Premium
Desferrioxamine related maculopathy: A case report
Author(s) -
Arora Anita,
Wren Siobhan,
Gregory Evans Kevin
Publication year - 2004
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.20090
Subject(s) - medicine , maculopathy , deferoxamine , retinopathy , blindness , toxicity , optic neuropathy , eye disease , optic nerve , ophthalmology , surgery , optometry , diabetes mellitus , endocrinology
Desferrioxamine is used for the treatment of chronic iron overload, acute iron poisoning, and certain anaemias. Ocular toxicity secondary to prolonged treatment with desferrioxamine may result in night blindness, visual field constriction, cataract, pigmentary retinopathy and optic neuropathy. To avoid such complications an ophthalmic screening has been suggested for patients taking desferrioxamine. We report an 81‐year‐old patient who developed irreversible ocular toxicity despite undergoing ophthalmic screening. Am. J. Hematol. 76:386–388, 2004. © 2004 Wiley‐Liss, Inc.